NCT00982982 is a EARLY_PHASE1 clinical trial of THC and Iomazenil in Schizophrenia, sponsored by Yale University.

Who is sponsoring NCT00982982?

NCT00982982 is sponsored by Yale University.

What drugs are being tested in NCT00982982?

Interventions in NCT00982982: THC and Iomazenil, Placebo (control).

What condition does NCT00982982 study?

NCT00982982 studies Schizophrenia, Mental Disorders, Psychotic Disorders.

Is NCT00982982 still recruiting?

NCT00982982 is currently completed. Last updated 5 December 2022.

Last reviewed 2022-12-05 · How we verify

NCT00982982

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Delta-9-THC and Iomazenil in Healthy Humans

Completed EARLY_PHASE1 Last updated 5 December 2022

What this trial tests

EARLY_PHASE1 trial testing THC and Iomazenil in Schizophrenia in 17 participants. Completed in 22 February 2013.

Timeline

11 February 2009

Primary endpoint
22 February 2013

22 February 2013

Quick facts

Lead sponsor	Yale University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Enrollment	17
Start date	11 February 2009
Primary completion	22 February 2013
Estimated completion	22 February 2013
Sites	1 location across United States

Drugs / interventions tested

THC and Iomazenil — full drug profile →
Placebo (control)

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Mental Disorders — all drugs for Mental Disorders →
Psychotic Disorders — all drugs for Psychotic Disorders →

Sponsor

Yale University

Who can join

Adults 18 to 55, male only, with Schizophrenia or Mental Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry.
Kurtz JS, Patel NA, Gendreau JL, Yang C, et al · · 2022 · cited 19× · PMID 36259015 · DOI 10.7759/cureus.29167

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00982982 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 5 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00982982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing